Physician profile
Mark D Corriere
NPI 1053350843
$402,004.36
in general payments reported to CMS, 2019-2025
36 companies · $28K in 2025
The $28K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $37K · 2021: $71K · 2022: $129K · 2023: $65K · 2024: $28K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Consulting Fee: $25K · Food and Beverage: $3,477 · Travel and Lodging: $3,366.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,461.44 |
| Consulting Fee | $25,100.00 |
| Food and Beverage | $3,476.73 |
| Travel and Lodging | $3,366.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $172,650.02 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Sanofi-Aventis U.S. LLC | $73,650.38 | 2019-2024 | |
| Ascensia Diabetes Care US INC. | $43,970.16 | 2022-2025 | |
| Lilly USA, LLC | $35,333.87 | 2019-2025 | Lyumjev, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $28,097.70 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $27,060.13 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $12,363.00 | 2019-2025 | Synthroid |
| Senseonics, Incorporated | $4,645.00 | 2019-2025 | Eversense |
| Zealand Pharma US, INC. | $3,009.25 | 2021-2022 | |
| Glaxosmithkline, LLC. | $123.87 | 2024 | Arexvy |
| Dexcom, INC. | $102.96 | 2019-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $101.40 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $77.72 | 2022-2024 | |
| Abbott Laboratories | $74.18 | 2022-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $68.62 | 2023-2025 | Unithroid |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $68.29 | 2021-2022 | |
| Amgen INC. | $60.66 | 2019-2024 | Repatha |
| Medtronic, INC. | $56.38 | 2024-2025 | Minimed 780g |
| Beta Bionics, INC. | $49.14 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Janssen Pharmaceuticals, INC | $45.30 | 2019 | |
| Corcept Therapeutics | $45.12 | 2022-2024 | Korlym |
| Radius Health, INC. | $42.26 | 2023-2025 | Tymlos |
| Cequr Corporation | $37.02 | 2023-2025 | Cequr Simplicity |
| Horizon Therapeutics Plc | $36.21 | 2020 | |
| Alexion Pharmaceuticals, INC. | $34.29 | 2022-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.65 | 2022-2025 | Jardiance |
| Sequel Med Tech, LLC | $23.71 | 2025 | Twiist |
| Ibsa Pharma INC. | $21.74 | 2023 | Licart, Tirosint |
| Grt US Holding, INC. | $18.60 | 2022 | |
| Tandem Diabetes Care, INC. | $18.57 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Halozyme INC | $18.03 | 2023 | |
| Antares Pharma, INC. | $16.92 | 2019 | |
| Tolmar, INC. | $13.79 | 2024 | |
| Lifescan, INC. | $13.65 | 2021 | |
| Companion Medical, INC. | $11.40 | 2019 | |
| Mannkind Corporation | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Corriere listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.